MYC is a well‐known oncogene in CRC, with its upregulation being linked to tumorigenesis progression.[23a] YY1 is also overexpressed in multiple cancer types, including CRC, where its overexpression is correlated with poor clinical outcomes.[28] Therefore, therapeutic strategies that target these two key transcription factors could potentially enhance treatment outcomes for CRC patients. The gene discussed is YY1; the disease is cancer.